Oral remibrutinib hits Phase 3 primary endpoint for inducible hives
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
Merck and Mayo Clinic launch AI-driven precision medicine partnership Merck and Mayo Clinic have officially kicked off a landmark R&D ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.